Epigral Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹746 Cr +27.1% YoYSee revenue, profit and what management said. You are viewing Q4 FY25.
E

Epigral Ltd

Q4 FY25Chemicals & Petrochemicals

Epigral Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management said on revenue, margins and capex.

Revenue
₹628Cr
+19.6% YoY
−2.6% QoQ
Net profit
₹87Cr
+13% YoY
−16.3% QoQ
Margin
28%
−2 pp YoY
0 pp QoQ
Price₹1,126
Market cap₹4.8K Cr
P/E17.8

The short version

Epigral Limited expects a volume growth CAGR of 10% to 15% over the next 5 years driven by capacity expansions. Epigral targets consistent volume growth of 10-15% CAGR over the next five years, driven by CAPEX expansions in CPVC resin, Epichlorohydrin, and chlorotoluene plants.

From Epigral Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Epigral Limited expects a volume growth CAGR of 10% to 15% over the next 5 years driven by capacity expansions.
  • Revenue growth is anticipated at 15% to 20% CAGR over the next 4-5 years, supported by new CAPEX and increased volumes.
  • Key growth drivers include ramp-up of CPVC resin and compound capacity, Epichlorohydrin (ECH) expansion, and the newly commissioned chlorotoluene plant.
  • The company aims to increase revenue contribution from the Derivatives & Specialty business from 54% in FY25 to around 70%.
  • The chlor-alkali integration with captive chlorine consumption is expected to improve, with target utilization at 80-90% by FY27.

2 more points from Epigral Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Epigral Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Planned CAPEX of around Rs. 450 crore for FY 2026 focused on expanding capacities in CPVC resin (addition of 75,000 tonnes to reach 1,50,000 tonnes) and Epichlorohydrin (expanding from 50,000 to 1,00,000 tonnes by H1 FY 2027).
  • Newly commissioned plants (CPVC, CPVC compound, chlorotoluene) expected to reach optimum utilization by end of FY 2026.
  • Minor debottlenecking CAPEX expected for chlor-alkali (caustic soda and chlorine integration) once operating at ~90% levels; no major chlor-alkali expansion planned currently.

2 more points from Epigral Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Epigral Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Epigral Ltd said on order book & pipeline — free account, 30 seconds.

Epigral Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Epigral Ltd Q4 FY25 results — key figures

Epigral Ltd Q4 FY25 reported results vs Q4 FY24, ₹ crore
₹ CrQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue628525+19.6%645-2.6%
Operating profit (EBITDA)173155+11.6%183-5.5%
Operating margin28%30%-2 pp28%0 pp
Profit before tax131113+15.9%154-14.9%
Net profit (PAT)8777+13%104-16.3%
EPS (₹)20.0818.45+8.8%24.00-16.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹746 Cr, net profit ₹64 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Atul (Q4 FY25)

    Consolidated revenue from operations for 2024-25: ₹5,583 cr, 18% increase YoY from ₹4,726 cr in 2023-24 (Page 36). Key concall takeaways from Atul Ltd's Q4…

  • Vidhi Specialty (Q4 FY25)

    109.5 Crs, up 40.2% YoY (from Rs. Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q4 FY25 earnings call — and how it ranks against sector…

  • Chemcon Speciality Chemicals (Q4 FY25)

    54.9 Crs, down 8% YoY from Rs. Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Valiant Organics (Q4 FY25)

    Q4-FY25 revenue from operations (consolidated) was INR 2,038 million, a 15.3% year-on-year (YoY) increase from INR 1,768 million in Q4-FY24 (Page 12 and 10)…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Epigral Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Epigral Ltd Q4 FY25 results?

Epigral Limited expects a volume growth CAGR of 10% to 15% over the next 5 years driven by capacity expansions. Epigral targets consistent volume growth of 10-15% CAGR over the next five years, driven by CAPEX expansions in CPVC resin, Epichlorohydrin, and chlorotoluene plants.

What is Epigral Ltd share price analysis?

Epigral Ltd currently shows a neutral. The stock trades at a P/E of 17.8 with a market cap of ₹4,828 Cr. Investors should review the full earnings analysis for detailed insights.

Is Epigral Ltd planning capital expenditure?

Planned CAPEX of around Rs. 450 crore for FY 2026 focused on expanding capacities in CPVC resin (addition of 75,000 tonnes to reach 1,50,000 tonnes) and Epichlorohydrin (expanding from 50,000 to 1,00,.

Keep Epigral Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.